Literature DB >> 25681440

A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells.

Mathangi Ramesh1, Navasona Krishnan2, Senthil K Muthuswamy3, Nicholas K Tonks4.   

Abstract

We used a loss-of-function screen to investigate the role of classical protein-tyrosine phosphatases (PTPs) in three-dimensional mammary epithelial cell morphogenesis and ERBB2 signaling. The study revealed a novel role for PTPD2 as a positive regulator of ERBB2 signaling. Suppression of PTPD2 attenuated the ERBB2-induced multiacinar phenotype in three-dimensional cultures specifically by inhibiting ERBB2-mediated loss of polarity and lumen filling. In contrast, overexpression of PTPD2 enhanced the ERBB2 phenotype. We also found that a lipid second messenger, phosphatidic acid, bound PTPD2 in vitro and enhanced its catalytic activity. Small molecule inhibitors of phospholipase D (PLD), an enzyme that produces phosphatidic acid in cells, also attenuated the ERBB2 phenotype. Exogenously added phosphatidic acid rescued the PLD-inhibition phenotype, but only when PTPD2 was present. These findings illustrate a novel pathway involving PTPD2 and the lipid second messenger phosphatidic acid that promotes ERBB2 function.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Breast Cancer; Cell Signaling; ERBB2; Lipid Signaling; Phosphatidic Acid; Phospholipase D; Phosphotyrosine Signaling; Protein-tyrosine Phosphatase; Receptor-tyrosine Kinase; Signal Transduction

Mesh:

Substances:

Year:  2015        PMID: 25681440      PMCID: PMC4392266          DOI: 10.1074/jbc.M114.627968

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells.

Authors:  G Fiucci; M Czarny; Y Lavie; D Zhao; B Berse; J K Blusztajn; M Liscovitch
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

Review 2.  Antibody therapeutics in cancer.

Authors:  Mark X Sliwkowski; Ira Mellman
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

3.  Receptor protein-tyrosine phosphatase α regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility.

Authors:  Benoit Boivin; Fauzia Chaudhary; Bryan C Dickinson; Aftabul Haque; Stephanie C Pero; Christopher J Chang; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

Review 4.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

Authors:  D Yu; M C Hung
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

Review 5.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

6.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.

Authors:  Gaofeng Fan; Guang Lin; Robert Lucito; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

8.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

Authors:  C R King; M H Kraus; S A Aaronson
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

9.  YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.

Authors:  J-M Huang; I Nagatomo; E Suzuki; T Mizuno; T Kumagai; A Berezov; H Zhang; B Karlan; M I Greene; Q Wang
Journal:  Oncogene       Date:  2012-06-11       Impact factor: 9.867

10.  Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.

Authors:  Navasona Krishnan; Dorothy Koveal; Daniel H Miller; Bin Xue; Sai Dipikaa Akshinthala; Jaka Kragelj; Malene Ringkjøbing Jensen; Carla-Maria Gauss; Rebecca Page; Martin Blackledge; Senthil K Muthuswamy; Wolfgang Peti; Nicholas K Tonks
Journal:  Nat Chem Biol       Date:  2014-05-20       Impact factor: 15.040

View more
  6 in total

1.  Phospholipase D2 restores endothelial barrier function by promoting PTPN14-mediated VE-cadherin dephosphorylation.

Authors:  Panfeng Fu; Ramaswamy Ramchandran; Mark Shaaya; Longshuang Huang; David L Ebenezer; Ying Jiang; Yulia Komarova; Stephen M Vogel; Asrar B Malik; Richard D Minshall; Guangwei Du; Nicholas K Tonks; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2020-04-23       Impact factor: 5.157

2.  The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion.

Authors:  Gareth W Fearnley; Katherine A Young; James R Edgar; Robin Antrobus; Iain M Hay; Wei-Ching Liang; Nadia Martinez-Martin; WeiYu Lin; Janet E Deane; Hayley J Sharpe
Journal:  Elife       Date:  2019-03-29       Impact factor: 8.140

3.  Scalable network estimation with L 0 penalty.

Authors:  Junghi Kim; Hongtu Zhu; Xiao Wang; Kim-Anh Do
Journal:  Stat Anal Data Min       Date:  2020-10-21       Impact factor: 1.051

Review 4.  The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond.

Authors:  Kayla E Wilson; Nuo Yang; Ashley L Mussell; Jianmin Zhang
Journal:  Genes (Basel)       Date:  2016-05-27       Impact factor: 4.096

5.  Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.

Authors:  Siwei Zhang; Gaofeng Fan; Yuan Hao; Molly Hammell; John Erby Wilkinson; Nicholas K Tonks
Journal:  Genes Dev       Date:  2017-10-24       Impact factor: 11.361

6.  High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.

Authors:  Elizabeth A White; Karl Münger; Peter M Howley
Journal:  mBio       Date:  2016-09-20       Impact factor: 7.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.